Salt Lake City, United States
Progenitor Life Sciences, LLC, established in 2012, operates in the Biotechnology sector, headquartered in the United States. The company is at the forefront of cellular immunotherapy and immune oncology, utilizing its proprietary technology to develop pluripotent stem cells for advanced immune cell differentiation and cancer-targeting therapies.
With its slogan, "Harnessing advanced technology to generate pluripotent stem cells for innovative immune cell differentiation and potent cancer-targeting therapies," Progenitor distinguishes itself as an innovator. The company offers a unique suite of solutions, including its patented iPSC sourcing and immune-compatibility technology, allowing the creation of allogeneic off-the-shelf CAR immune cell constructs from diverse cell sources.
The company's strategic partnerships with pharma and biotech entities underscore its collaborative strength and market relevance. Notably, Progenitor secured a $110.00K Seed Round investment on 31 December 2013.
